Trial Profile
Effect of Interleukin-1 Receptor Antagonist on Insulin Sensitivity in Obese, Insulin Resistant Individuals.
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 09 Feb 2022
Price :
$35
*
At a glance
- Drugs Anakinra (Primary)
- Indications Insulin resistance
- Focus Therapeutic Use
- 18 Dec 2009 Planned end date changed from 1 Jan 2010 to 1 Jul 2010 as reported by ClinicalTrials.gov
- 18 Dec 2009 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov
- 06 Jul 2009 New trial record